Eventhough of the progress indevelopment of several anticancer drugs,chemoresistance is still major hindrancethat results in the failure of treatment . Multiple factors are involved indevelopment of chemoresistance such as inactivation of chemotherapy drug,alteration in tumor suppressor gene, anti and pro apoptotic proteins. In lungcancer,SomeNSCLC patients have inherently chemo-resistant disease while some become chemo-resistantduring the course of treatment especially to platinum compound (cisplatin).The molecularmechanisms behind development of platinum resistance is still unclear. Most ofthe time resistance may develope during early sittings or cycle of chemotherapy. This may be because of reduced accumulation of cisplatin atincellular level which result in changes in expression of oncogene and alsoregulatory protein. (Adams and Harvey, 2010, Barr and O’Byrne, 2010). Overcoming thischemoresistance has become a major focus of many studies.
Insight ofmolecules that which help in the development of drug resistance and metastasiscould offer promising biomarkers for early detection and as therapeutic targets for effective controland treatment of the disease.Earlierthe role of biomarker it has been studied on breast cancer selected out for drug resistance which shows high levels of the multifunctional proteincross linking enzyme tissue transglutaminase (TG2). Studies have shown that overexpression of TG2 in cancer cell line develop cancer cell more invasive and metastaticso cell become resistant to drug (Chen, et al.
2002).undertakenin numerous breast cancer cell lines have shown that higher expression of TG2makesthe cancer cells more invasive and metastatic as well as conferring resistanceto variousdrugs(Chen, et al. 2002). Some other factors are also involved along with TG2to confirmed some hypotheses have been suggestedthat this may be due to the interactionbetween TG2 and the transcription factor Nuclear Factor-kappa B (NF?B).
